{"id":23421,"date":"2019-01-14T15:14:32","date_gmt":"2019-01-14T13:14:32","guid":{"rendered":"https:\/\/www.asperbio.com\/?page_id=23421"},"modified":"2021-09-28T10:46:16","modified_gmt":"2021-09-28T07:46:16","slug":"bulloosse-epidermoluusiga-seotud-geenide-sekveneerimine","status":"publish","type":"page","link":"https:\/\/www.asperbio.com\/et\/asper-dermatology-testid\/bulloosse-epidermoluusiga-seotud-geenide-sekveneerimine\/","title":{"rendered":"Bulloosse epidermol\u00fc\u00fcsiga seotud geenide sekveneerimine"},"content":{"rendered":"<h2 style=\"padding-left: 5px;\"><span style=\"color: #6859a2;\">Bulloosse epidermol\u00fc\u00fcsiga<br \/>\nseotud geenide sekveneerimine<\/span><\/h2>\n<div class=\"sm_post_content\" style=\"background: url('https:\/\/www.asperbio.com\/wp-content\/uploads\/Asper-Dermatology-01.png') repeat-y; padding-left: 40px;\">\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Geen:<\/strong><\/td>\n<td><em>CD151, CDSN, CHST8, COL7A1, COL17A1, DSG1, DSP, DST, EXPH5, FERMT1, ITGA3, ITGB4, ITGA6, JUP, KRT1, KRT10, KRT14, KRT5, KRT9, LAMA3, LAMB3, LAMC2, MMP1, PLEC, PKP1, TGM5<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #6859a2; background-color: #6859a2; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Metoodika:<\/strong><\/td>\n<td>Kodeeriva piirkonna sekveneerimine (NGS).<br \/>\nKoopiaarvu muutuste bioinformaatiline anal\u00fc\u00fcs (CNV). CNV leidude kinnitamine teise meetodiga toimub lisaanal\u00fc\u00fcsina, vastavalt hinnakirjale.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #6859a2; background-color: #6859a2; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Testi valmimisaeg:<\/strong><\/td>\n<td>6-9 n\u00e4dalat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #6859a2; background-color: #6859a2; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>N\u00f5uded proovi-materjalile:<\/strong><\/td>\n<td>2-4 ml t\u00e4isverd antikoagulandiga EDTA (lilla korgiga katsuti)<\/p>\n<p>1 \u00b5g DNA-d elueerituna TE, AE puhvris v\u00f5i steriilses vees, kontsentratsiooniga 100-250 ng\/\u00b5l<br \/>\nDNA saata toatemperatuuril v\u00f5i k\u00fclmutatuna. A260\/A280 suhe peaks olema 1.8-2.0. DNA peab agaroosgeelis pikkusmarkeri juuresolekul olema detekteeritav \u00fche tervikliku b\u00e4ndina.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #6859a2; background-color: #6859a2; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Tellimine:<\/strong><\/td>\n<td>Proovimaterjal saata koos <span style=\"color: #6859a2;\"><strong><a style=\"color: #6859a2;\" href=\"https:\/\/www.asperbio.com\/wp-content\/uploads\/Asper-Dermatology-saatekiri.doc\">saatekirjaga<\/a><\/strong><\/span> Asper Biogene laborisse<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #6859a2; background-color: #6859a2; height: 2px; border: none; width: 100%;\" \/>\n<\/div>\n<p><strong>N\u00e4idustused geneetiliseks testimiseks<\/strong>:<br \/>\n1. Kliinilise diagnoosi kinnitamine<br \/>\n2. Bulloosse epidermol\u00fc\u00fcsi\u00a0t\u00fc\u00fcpide\/alat\u00fc\u00fcpide ja teiste geneetiliselt\/fenot\u00fc\u00fcpiliselt seotud haiguste diferentsiaaldiagnostika<br \/>\n3. Prenataalne diagnostika teadaoleva perekondliku muutuse korral<br \/>\n4. Geneetiline konsultatsioon<\/p>\n<p><strong>P\u00e4rilik<\/strong> <strong>bulloosne epidermol\u00fc\u00fcs<\/strong> (BE) on geneetiliste haiguste grupp, mille puhul on iseloomulikeks s\u00fcmptomiteks v\u00e4ga <strong>\u00f5rn nahk ja villide teke nahale<\/strong> ja <strong>limaskestadele<\/strong> v\u00e4iksemagi vigastuse v\u00f5i h\u00f5\u00f5rumise t\u00f5ttu. BE on kliiniliselt ja geneetiliselt v\u00e4ga heterogeenne. Eristatakse haiguse nelja p\u00f5hit\u00fc\u00fcpi koos alat\u00fc\u00fcpidega. K\u00f5igi t\u00fc\u00fcpide puhul on v\u00f5imalik nii kerge kui raske haigusvorm. Haigust\u00fc\u00fcpide klassifitseerimise aluseks on villide esinemine erinevates naha piirkondades: lihtvorm (epidermaalne), liiduseline (basaalmembraani <em>lucida<\/em> kihti haarav), d\u00fcstroofiline (basaalmembraania alune) ja Kindleri t\u00fc\u00fcpi (erinevaid kihte haarav).\u00a0Klassifikatsioon alat\u00fc\u00fcpidesse toimub kliiniliste s\u00fcmptomite, p\u00e4rilikkuse viisi, DNA ja valgu tasemel muutuse alusel.\u00a0BE erinevate alat\u00fc\u00fcpidega on seotud patogeensed muutused v\u00e4hemalt 18 geenis, mis kodeerivad epidermise, basaalmembraani ja dermise valke. BE erinevatele t\u00fc\u00fcpidele iseloomulikud fenot\u00fc\u00fcbid korreleeruvad kindlate geenidega, milles muutus esineb. Samas v\u00f5ivad erinevad geenid olla seotud v\u00e4ga sarnaste BE fenot\u00fc\u00fcpidega.<\/p>\n<p>Testiga on kaetud teadaolevate BE t\u00fc\u00fcpide\/alat\u00fc\u00fcpide ja teiste geneetiliselt\/fenot\u00fc\u00fcpiliselt seotud haiguste geneetilised p\u00f5hjused.<\/p>\n<p>Vastavalt BE t\u00fc\u00fcbile v\u00f5ib haigus p\u00e4randuda autosoom-dominantsel v\u00f5i autosoom-retsessiivsel teel.<\/p>\n<p>BE k\u00f5ikide t\u00fc\u00fcpide esinemissagedus kokku on hinnanguliselt 11: 1 000 000. Haiguse lihtvormi sagedus on 6:1 000 000, liiduselise BE sagedus 0,5:1 000 000, d\u00fcstroofilise vormi puhul 3,3:1 000 000 ja Kinderi t\u00fc\u00fcpi BE on leitud 250 inimesel maailmas.<\/p>","protected":false},"excerpt":{"rendered":"<p>Bulloosse epidermol\u00fc\u00fcsiga seotud geenide sekveneerimine Geen: CD151, CDSN, CHST8, COL7A1, COL17A1, DSG1, DSP, DST, EXPH5, FERMT1, ITGA3, ITGB4, ITGA6, JUP, KRT1, KRT10, KRT14, KRT5, KRT9, LAMA3, LAMB3, LAMC2, MMP1, PLEC, PKP1, TGM5 Metoodika: Kodeeriva piirkonna sekveneerimine (NGS). Koopiaarvu muutuste bioinformaatiline anal\u00fc\u00fcs (CNV). CNV leidude kinnitamine teise meetodiga toimub lisaanal\u00fc\u00fcsina, vastavalt hinnakirjale. Testi valmimisaeg: 6-9 n\u00e4dalat [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":23406,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-23421","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/23421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/comments?post=23421"}],"version-history":[{"count":3,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/23421\/revisions"}],"predecessor-version":[{"id":27912,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/23421\/revisions\/27912"}],"up":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/23406"}],"wp:attachment":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/media?parent=23421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}